Important European patent for iNKT technology secured

Securing intellectual property across major jurisdictions is always important to small companies working on innovative technology and a de-risking factor for investors.

Our biotech Investment, Arovella Therapeutics (ASX:ALA) has secured a key patent in Europe for the company’s lead product, ALA-101.

This is ALA’s iNKT cell therapy platform, the same product which has performed so well in pre-clinical studies and that we are keen to see move into a Phase 1 study.

The patent covers the manufacture of CAR-iNKT cells and can be found on the European Patent Office website.

ALA has patents pending in other major jurisdictions as below:

ALA is currently working on combining ALA-101 with Imugene’s onCARlytics platform to potentially target solid tumours, which make up the vast majority of cancers.

What’s next for ALA? Securing additional patents in pending jurisdictions. Beyond that, we’re particularly looking forward to the in-vitro and in-vivo study outcomes from the combined ALA + Imugene therapy that’s due in Q1 2023 and Q2 2023.